ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 라임병 백신 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2024년 10억 4,000만 달러에서 2025년에는 11억 2,000만 달러에 달하고, CAGR 7.5%로 확대될 전망입니다. 지난 몇 년간의 성장은 서식지의 확대에 따른 인간과 진드기의 접촉 기회 증가, 유행 지역에서의 헬스 케어 인프라의 정비, 감염증 백신 조사 자금 증가, 예방적인 여행이나 직업 건강 관리에 대한 소비자 관심 증가 등이 요인이 되고 있습니다.
라임병 백신 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 14억 7,000만 달러에 달하고 CAGR은 7.1%가 될 전망입니다. 예측기간 성장은 라임병 발생률 상승, 진드기 매개 리스크에 대한 공중보건 의식 증가, 백신 개발에 대한 정부 투자 증가, 예방적 매개 생물 감염 대책 솔루션에 대한 수요 증가, 백신 플랫폼의 생명공학 분야에서의 협력 확대로 인한 전망입니다. 예측 기간의 주요 동향으로는 mRNA 및 재조합 라임병 백신의 기술적 진보, 라임병 백신 접종의 정기 예방접종 프로그램에의 통합, 다병원체 진드기 매개 질환 백신의 혁신, 세계의 백신 개발에 있어서의 협업 파트너십, 신규 전달 시스템의 진전을 들 수 있습니다.
라임병의 만연 확대는 미래의 라임병 백신 시장의 확대를 견인할 것으로 예측됩니다. 라임병은 보렐리아균에 의한 진드기 매개 질환이며, 발열, 권태감, 발진 등의 증상을 일으키고, 치료를 게을리하면 관절, 심장, 신경계에 영향을 미치는 심각한 합병증을 초래할 수 있습니다. 라임병 증례 증가는 주로 기후 변화에 기인하고 있으며, 기온의 상승과 온난한 겨울이 진드기의 서식지역을 확대하고, 감염된 진드기에 인간이 노출할 기회를 늘리고 있습니다. 라임병 백신은 면역계를 자극하여 보렐리아균을 인식 및 격퇴시킴으로써 감염을 예방하고 질병 위험을 줄입니다. 이 백신은 장기적인 보호 효과를 제공하고 공중 보건 개선에 기여합니다. 예를 들어, 미국 질병 예방관리센터(CDC)의 보고에 따르면 2023년 미국에서 공식적으로 기록된 라임병 사례는 약 8만 9,000건이었지만, 추정에서는 연간 약 47만 6,000명이 진단 및 치료를 받고 있을 가능성이 있습니다. 이와 같이 라임병의 유병률 상승이 라임병 백신 시장의 성장을 가속하고 있습니다.
헬스케어 지출 증가도 라임병 백신 시장의 성장을 가속할 것으로 예측됩니다. 헬스케어 지출이란, 건강의 유지 및 향상을 목적으로 한 의료 서비스, 치료, 시설, 연구, 공중 보건 시책에 할당할 수 있는 재정 자원의 총액을 가리킵니다. 장기적이고 고액의 치료가 필요한 만성 질환 증가로 건강 관리 서비스에 대한 수요가 증가하고 있습니다. 건강 관리 지출 증가는 연구, 임상시험 및 제조 공정에 추가 자금을 제공함으로써 라임병 백신의 개발을 지원합니다. 이것은 백신 기술을 향상시키고 높은 위험층에 대한 접근성과 효능을 모두 향상시킵니다. 예를 들어, 2024년 5월에 영국 국가 통계국이 발표한 데이터에 따르면, 2023년 영국의 헬스케어 지출은 명목 기준으로 5.6% 증가했으며, 2022년 대비 0.9%의 상승을 보였습니다. 따라서 의료 지출 증가는 라임병 백신 시장의 성장에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 라임병 백신 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 라임병 백신 시장 : 성장률 분석
세계의 라임병 백신 시장 실적 : 규모와 성장, 2019-2024년
세계의 라임병 백신 시장 예측 : 규모와 성장, 2024-2029년, 2034F
세계의 라임병 백신 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 라임병 백신 시장 : 백신유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
재조합 백신
서브 유닛 백신
생약독 백신
기타 백신 유형
세계의 라임병 백신 시장 : 기술별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
림프구 형질전환시험
요중 항원 검사
면역형광염색법 핵산검사
혈청학적 검사
세계의 라임병 백신 시장 : 연령층별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
소아
성인
고령자
세계의 라임병 백신 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
병원 및 진료소
약국
정부 공급
기타 유통 채널
세계의 라임병 백신 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
병원
임상 실험실
기타 최종 사용자
세계의 라임병 백신 시장 : 재조합 백신 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
단백질 기반 재조합 백신
벡터 기반 재조합 백신
DNA 기반 재조합 백신
세계의 라임병 백신 시장 : 서브 유닛 백신 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
단백질 아단위 백신
다당체 아단위 백신
결합 아단위 백신
세계의 라임병 백신 시장 : 생약독 백신 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
자연 약독화 백신
유전자 약독화 백신
온도 민감성 약독 백신
세계의 라임병 백신 시장 : 기타 백신 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
톡소이드 백신
불활성화 백신
벡터 백신
제7장 지역별/국가별 분석
세계의 라임병 백신 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
세계의 라임병 백신 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
라임병 백신 시장 : 경쟁 구도
라임병 백신 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Boehringer Ingelheim GmbH : 개요, 제품 및 서비스, 전략 및 재무 분석
University of Pennsylvania : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Elanco Animal Health Incorporated
Elanco Animal Health Incorporated
Zoetis Inc.
Emergent BioSolutions Inc.
Bavarian Nordic A/S
Aegis Life Inc.
Bioveta as
Dynavax Technologies Corporation
Valneva SE
MassBiologics of UMass Chan Medical School
Inovio Pharmaceuticals Inc.
US Biologic Inc.
Blue Lake Biotechnology Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
라임병 백신 시장(2029년) : 새로운 기회를 제공하는 국가
라임병 백신 시장(2029년) : 새로운 기회를 제공하는 부문
라임병 백신 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Lyme disease vaccines are biological preparations developed to stimulate the immune system to identify and combat Borrelia burgdorferi, the bacteria that cause Lyme disease, thereby preventing infection after a tick bite. These vaccines function by prompting the body to produce specific antibodies that neutralize the bacteria, lowering the likelihood of disease transmission and related complications, and serving as an important tool for controlling Lyme disease in regions where it is common.
The key vaccine types for Lyme disease include recombinant vaccines, subunit vaccines, live attenuated vaccines, and others. Recombinant vaccines are created using genetic engineering methods to generate specific proteins (antigens) from Borrelia burgdorferi, the bacteria responsible for Lyme disease. They employ various technologies such as the lymphocytic transformation test, urine antigen testing, immunofluorescent staining, nucleic acid testing, and serological testing, and are intended for age groups including pediatric, adult, and geriatric populations. Distribution channels include hospitals and clinics, pharmacies, government supply, and others, serving end users such as hospitals, clinical laboratories, and additional healthcare settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The Lyme disease vaccine market research report is one of a series of new reports from The Business Research Company that provides Lyme disease vaccine market statistics, including Lyme disease vaccine industry global market size, regional shares, competitors with a Lyme disease vaccine market share, detailed Lyme disease vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the Lyme disease vaccine industry. This Lyme disease vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The Lyme disease vaccine market size has grown strongly in recent years. It will grow from $1.04 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period resulted from growing human-tick interaction due to habitat expansion, rising healthcare infrastructure in endemic regions, increasing research funding for infectious-disease vaccines, and greater consumer interest in preventive travel or occupational health.
The Lyme disease vaccine market size is expected to see strong growth in the next few years. It will grow to $1.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period will be driven by the rising incidence of Lyme disease, growing public health awareness of tick-borne risks, increasing government investment in vaccine development, rising demand for preventive vector-borne disease solutions, and expanding collaboration in biotech for vaccine platforms. Major trends in the forecast period include technological advancements in mRNA and recombinant Lyme vaccines, the integration of Lyme vaccination into routine immunization programs, innovations in multi-pathogen tick-borne disease vaccines, collaborative global vaccine development partnerships, and progress in novel delivery systems.
The growing prevalence of Lyme disease is expected to drive the expansion of the Lyme disease vaccine market in the future. Lyme disease is a tick-borne illness caused by Borrelia bacteria, which can lead to symptoms such as fever, fatigue, rashes, and, if left untreated, severe complications affecting the joints, heart, or nervous system. The rise in Lyme disease cases is largely attributed to climate change, as warmer temperatures and milder winters are expanding tick habitats, thereby increasing human exposure to infected ticks. Lyme disease vaccines help prevent the infection by stimulating the immune system to recognize and fight off Borrelia bacteria, thereby reducing the risk of disease. These vaccines offer long-term protection, which contributes to better public health outcomes. For example, the Centers for Disease Control and Prevention (CDC) reported that in 2023, approximately 89,000 cases of Lyme disease were officially recorded in the U.S., although estimates suggest that nearly 476,000 people may be diagnosed and treated for the disease annually. Thus, the rising prevalence of Lyme disease is fueling the growth of the Lyme disease vaccine market.
Rising healthcare expenditure is also expected to drive growth in the Lyme disease vaccine market. Healthcare expenditure refers to the total amount of financial resources allocated to medical services, treatments, facilities, research, and public health initiatives aimed at improving or maintaining health. The increasing demand for healthcare services is driven by the rising prevalence of chronic diseases that require long-term, costly treatments. The growth in healthcare spending supports the development of Lyme disease vaccines by providing additional funding for research, clinical trials, and production processes. This facilitates the advancement of vaccine technologies, improving both accessibility and effectiveness for high-risk populations. For example, in May 2024, the Office for National Statistics reported that healthcare expenditure in the UK increased by 5.6% in nominal terms in 2023, marking a 0.9% rise from 2022. Consequently, the rise in healthcare expenditure is contributing to the growth of the Lyme disease vaccine market.
Leading companies in the Lyme disease vaccine market are focusing on advancing their late-stage product candidates, including booster vaccines, to meet unmet medical needs, improve immune protection, and streamline vaccination schedules. Booster vaccines are additional doses given after the initial vaccination to enhance or restore long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology firm, reported positive results from a Phase 2 study of its Lyme disease vaccine candidate, VLA15. This multivalent vaccine targets OspA proteins on Borrelia bacteria, triggering the immune system to produce antibodies that block bacterial infection when ticks bite. The study demonstrated a strong immune response and a favorable safety profile following a third booster dose, with results consistent with those seen after previous annual booster shots. This suggests that the vaccine can provide continued protection against Lyme disease, with the potential for a yearly pre-exposure booster dose before each Lyme season, making vaccination easier for at-risk individuals.
Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.
North America was the largest region in the Lyme disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Lyme disease vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Lyme disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The Lyme disease vaccine market consists of sales of pre-filled syringes, single or multi-dose vials, vaccine kits, storage and delivery equipment, and cold-chain packaging materials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Lyme Disease Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on lyme disease vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for lyme disease vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lyme disease vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Vaccine Type: Recombinant Vaccines; Subunit Vaccines; Live Attenuated Vaccines; Other Vaccine Types
2) By Technology: Lymphocytic Transformation Test; Urine Antigen Testing; Immunofluorescent Staining Nucleic Acid Test; Serological Test
3) By Age Group: Pediatric; Adult; Geriatric
4) By Distribution Channel: Hospitals And Clinics; Pharmacies; Government Supply; Other Distribution Channels
5) By End User: Hospitals; Clinical Laboratories; Other End Users
2) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines
3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines; Genetically Attenuated Vaccines; Temperature-Sensitive Attenuated Vaccines
4) By Other Vaccine Types: Toxoid Vaccines; Inactivated Vaccines; Vectored Vaccines
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Boehringer Ingelheim GmbH; University of Pennsylvania; Elanco Animal Health Incorporated; Elanco Animal Health Incorporated; Zoetis Inc.; Emergent BioSolutions Inc.; Bavarian Nordic A/S; Aegis Life Inc.; Bioveta a.s.; Dynavax Technologies Corporation; Valneva SE; MassBiologics of UMass Chan Medical School; Inovio Pharmaceuticals Inc.; US Biologic Inc.; Blue Lake Biotechnology Inc.
Countries:
Table of Contents
1. Executive Summary
2. Lyme Disease Vaccine Market Characteristics
3. Lyme Disease Vaccine Market Trends And Strategies
4. Lyme Disease Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Lyme Disease Vaccine Growth Analysis And Strategic Analysis Framework
5.1. Global Lyme Disease Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lyme Disease Vaccine Market Growth Rate Analysis
5.4. Global Lyme Disease Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lyme Disease Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lyme Disease Vaccine Total Addressable Market (TAM)
6. Lyme Disease Vaccine Market Segmentation
6.1. Global Lyme Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Vaccines
Subunit Vaccines
Live Attenuated Vaccines
Other Vaccine Types
6.2. Global Lyme Disease Vaccine Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lymphocytic Transformation Test
Urine Antigen Testing
Immunofluorescent Staining Nucleic Acid Test
Serological Test
6.3. Global Lyme Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric
Adult
Geriatric
6.4. Global Lyme Disease Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Pharmacies
Government Supply
Other Distribution Channels
6.5. Global Lyme Disease Vaccine Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinical Laboratories
Other End Users
6.6. Global Lyme Disease Vaccine Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.7. Global Lyme Disease Vaccine Market, Sub-Segmentation Of Subunit Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Protein Subunit Vaccines
Polysaccharide Subunit Vaccines
Conjugate Subunit Vaccines
6.8. Global Lyme Disease Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Naturally Attenuated Vaccines
Genetically Attenuated Vaccines
Temperature-Sensitive Attenuated Vaccines
6.9. Global Lyme Disease Vaccine Market, Sub-Segmentation Of Other Vaccine Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Toxoid Vaccines
Inactivated Vaccines
Vectored Vaccines
7. Lyme Disease Vaccine Market Regional And Country Analysis
7.1. Global Lyme Disease Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lyme Disease Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
